LY96 and colorectal cancer: Furthermore, RA acts as a considerably potent antitumor candidate against colitis-associated colorectal cancer by inhibiting toll-like receptor-4 (TLR4) and myeloid differentiation factor 2 (MD-2) complex-mediated nuclear factor-kappa B (NF-κB) and STAT3 activation [33].